Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epoetin alfa biosimilar - Apotex/Apobilogix

Next Previous
X
Search
Drug Profile

Epoetin alfa biosimilar - Apotex/Apobilogix

Alternative Names: APO-EPO

Latest Information Update: 14 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apotex
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 14 Oct 2021 Epoetin alfa is still in phase III trials for Anemia in Czech Republic, Hungary, Slovakia, Bulgaria, Greece, Slovakia and Romania (EudraCT2011-005057-31)
  • 23 Jan 2018 Phase III development of epoetin alfa biosimilar is ongoing Bulgaria (Apobilogix pipeline, January 2018)
  • 23 Jan 2018 Phase III development of epoetin alfa biosimilar is ongoing Czech Republic (Apobilogix pipeline, January 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top